Related Experiment Video
Updated: Apr 15, 2026

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Guotai Xu1, J Ross Chapman2, Inger Brandsma3
1Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Abstract:
Error-free repair of DNA double-strand breaks (DSBs) is achieved by homologous recombination (HR), and BRCA1 is an important factor for this repair pathway. In the absence of BRCA1-mediated HR, the administration of PARP inhibitors induces synthetic lethality of tumour cells of patients with breast or ovarian cancers. Despite the benefit of this tailored therapy, drug resistance can occur by HR restoration. Genetic reversion of BRCA1-inactivating mutations can be the underlying mechanism of drug resistance, but this does not explain resistance in all cases. In particular, little is known about BRCA1-independent restoration of HR. Here we show that loss of REV7 (also known as MAD2L2) in mouse and human cell lines re-establishes CTIP-dependent end resection of DSBs in BRCA1-deficient cells, leading to HR restoration and PARP inhibitor resistance, which is reversed by ATM kinase inhibition. REV7 is recruited to DSBs in a manner dependent on the H2AX-MDC1-RNF8-RNF168-53BP1 chromatin pathway, and seems to block HR and promote end joining in addition to its regulatory role in DNA damage tolerance. Finally, we establish that REV7 blocks DSB resection to promote non-homologous end-joining during immunoglobulin class switch recombination. Our results reveal an unexpected crucial function of REV7 downstream of 53BP1 in coordinating pathological DSB repair pathway choices in BRCA1-deficient cells.
Insights
Loss of REV7 restores homologous recombination (HR) DNA repair in BRCA1-deficient cells, leading to PARP inhibitor resistance. This REV7 function is downstream of 53BP1 and impacts DNA repair pathway choices.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Homologous recombination (HR) is crucial for error-free DNA double-strand break (DSB) repair.
- BRCA1 deficiency leads to synthetic lethality with PARP inhibitors in certain cancers.
- Drug resistance can arise from HR restoration, but mechanisms of BRCA1-independent HR restoration are unclear.
Purpose of the Study:
- To investigate the mechanisms of BRCA1-independent HR restoration.
- To identify novel factors involved in DNA repair pathway choice in BRCA1-deficient cells.
- To understand the role of REV7 in DNA repair and PARP inhibitor resistance.
Main Methods:
- Utilized mouse and human cell lines.
- Investigated DNA repair pathways including HR and non-homologous end-joining (NHEJ).
- Analyzed protein recruitment to DSBs using chromatin pathways.
- Examined the effect of ATM kinase inhibition.
Main Results:
- Loss of REV7 (MAD2L2) re-establishes CTIP-dependent end resection in BRCA1-deficient cells.
- REV7 loss restores HR, conferring PARP inhibitor resistance.
- REV7 recruitment to DSBs depends on the H2AX-MDC1-RNF8-RNF168-53BP1 pathway.
- REV7 blocks DSB resection to promote NHEJ during immunoglobulin class switch recombination.
- ATM kinase inhibition reverses REV7-mediated resistance.
Conclusions:
- REV7 plays a critical role in blocking HR and promoting NHEJ in BRCA1-deficient cells.
- REV7 acts downstream of 53BP1 in coordinating DSB repair pathway selection.
- Targeting REV7 may offer strategies to overcome PARP inhibitor resistance.
Related Concept Videos
Restarting Stalled Replication Forks
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Long-patch Base Excision Repair
Homologous Recombination
Base Excision Repair
The first step of...

